Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | ACHE | P22303 | 9/20 | 0.53 |
| ▸ | BCHE | P06276 | 4/20 | 0.53 |
| ▸ | BACE1 | P56817 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3322725 | 0.89 | MEN1 (0.50) | PKML3MBTL1ACHEBCHEBACE1 | |
| SCHEMBL27780900 | 0.88 | MEN1 (0.51) | PKML3MBTL1ACHEGAAKMT2A | |
| SCHEMBL3323359 | 0.84 | CXCR3 (0.50) | PKML3MBTL1ACHEBCHEBACE1 | |
| SCHEMBL3323699 | 0.84 | DRD2 (0.62) | PKML3MBTL1ACHEKDM4EGAA | |
| SCHEMBL19500907 | 0.83 | ACHE (0.60) | L3MBTL1ACHEBCHEBACE1KDM4E | |
| SCHEMBL13361813 | 0.82 | DRD2 (0.53) | PKML3MBTL1ACHEKDM4EGAA | |
| SCHEMBL3323191 | 0.82 | DRD2 (0.52) | PKML3MBTL1ACHEKDM4EGAA | |
| SCHEMBL27802452 | 0.78 | SSTR5 (0.46) | GAAKMT2AMEN1SIGMAR1LMNA | |
| SCHEMBL3320533 | 0.78 | ACHE (0.53) | ACHEBCHEBACE1KDM4EGAA | |
| SCHEMBL27780878 | 0.76 | CARM1 (0.50) | KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8933101-B2 | Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-13 | — | — | US | claimed |
| US-20100120860-A1 | THIA(DIA)ZOLES AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN-CILAG S.A., (ES) | 2010-05-13 | — | — | US | claimed |
| EP-2148879-A1 | THIA(DIA)ZOLES AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2010-02-03 | — | — | EP | claimed |
| WO-2008128996-A1 | THIA(DIA)ZOLES AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-10-30 | — | — | WO | claimed |
| US-8933101-B2 | Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-13 | — | — | US | disclosed |
| US-8933101-B2 | Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-13 | — | — | US | disclosed |
| US-8933101-B2 | Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-13 | — | — | US | disclosed |
| US-20100120860-A1 | THIA(DIA)ZOLES AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN-CILAG S.A., (ES) | 2010-05-13 | — | — | US | disclosed |
| US-20100120860-A1 | THIA(DIA)ZOLES AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN-CILAG S.A., (ES) | 2010-05-13 | — | — | US | disclosed |
| US-20100120860-A1 | THIA(DIA)ZOLES AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN-CILAG S.A., (ES) | 2010-05-13 | — | — | US | disclosed |
| EP-2148879-A1 | THIA(DIA)ZOLES AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2010-02-03 | — | — | EP | disclosed |
| WO-2008128996-A1 | THIA(DIA)ZOLES AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120860-A1 | THIA(DIA)ZOLES AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | GRIN2A, DRD2, GRIN2C | PKM 3165/4885L3MBTL1 4733/4885ACHE 776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.